BOSTON — Researchers at a consortium of seven major cancer centers published Phase III trial results Saturday showing that a new CAR-T cell immunotherapy, designated CART-GD3, achieved complete remission in 94 percent of patients with advanced diffuse large B-cell lymphoma — one of the most common and lethal forms of blood cancer. The trial enrolled 847 patients across 23 countries who had failed at least two prior lines of treatment, making them among the most difficult cases in oncology. At the 24-month follow-up, 81 percent of those who achieved remission remained disease-free, numbers that senior oncologists called unprecedented for this patient population.
CART-GD3 works by engineering a patient's own immune T-cells to recognize and destroy cancer cells bearing a specific protein marker called GD3, which is expressed at abnormally high levels in several cancer types but is largely absent from healthy adult tissue. Earlier generations of CAR-T therapies targeted markers that also appear on healthy cells, causing significant side effects and limiting the doses that could safely be administered. The GD3 targeting approach, developed over seven years at the Dana-Farber Cancer Institute, dramatically reduces off-target toxicity while improving the therapy's ability to infiltrate solid tumors — a problem that had limited CAR-T's effectiveness to blood cancers.
The implications extend beyond lymphoma. GD3 is also overexpressed in triple-negative breast cancer, glioblastoma, and several forms of sarcoma — cancers that have historically been resistant to most targeted therapies. Companion trials testing CART-GD3 in these indications are already underway, and early data from the glioblastoma arm, presented at a conference last month, showed a 67 percent objective response rate in patients who had previously exhausted all standard treatment options. Researchers caution that early-phase data for aggressive brain cancers are notoriously difficult to interpret, but called the signal "unmistakably encouraging."
The therapy is personalized to each patient: a blood draw is used to extract T-cells, which are then genetically modified in a laboratory using CRISPR-Cas9 technology over a period of approximately two weeks, before being infused back into the patient. The manufacturing complexity means the therapy is currently available at only a small number of specialized treatment centers. Cost is a significant barrier: the list price for the procedure is expected to be approximately $850,000 per patient, though developers are in discussions with insurers and health systems about coverage frameworks. Access advocates have already called the price "unconscionable" for a therapy that could save thousands of lives annually.
The FDA fast-tracked the therapy's review process, and an advisory committee is scheduled to meet in June to evaluate the new data. Regulatory approval in the United States could come as early as September, with the European Medicines Agency expected to follow within months of an FDA decision. The therapy's co-developer, BioVenture Sciences, saw its stock price more than double in after-hours trading Friday when embargoed results were released to investors ahead of the full publication in the New England Journal of Medicine.
For patients in the trial, the results are transformative in the most literal sense. Maria Santos, 44, a mother of three from São Paulo who enrolled after her lymphoma returned for a third time, said she had been given a six-month prognosis before entering the trial. Eighteen months later, she has no detectable cancer. "I came to the trial because I had nothing left," she told CMN. "I am leaving it because I have everything." Her oncologist, Dr. Camille Ross of the Dana-Farber Institute, said Santos represents a pattern, not an exception. "We are seeing this again and again," Dr. Ross said. "It is very hard for physicians, who are trained to be cautious, not to use the word 'cure.'"